Cusumano V, Genovese F, Mancuso G, Carbone M, Fera M T, Teti G
Istituto di Microbiologia, Facolta di Medicina e Chirurgia, Universita degli Studi di Messina, Italy.
Infect Immun. 1996 Jul;64(7):2850-2. doi: 10.1128/iai.64.7.2850-2852.1996.
We investigated the role of interleukin-10 (IL-10) in a neonatal mouse model of lethal group B streptococci (GBS) sepsis. Plasma IL-10 levels significantly increased at 24 and 48 h after GBS inoculation. Neutralization of IL-10 with specific antibodies had no effect on lethality. Administration of recombinant IL-10 at 20 or 4 h before challenge, but not at later times, resulted in decreased tumor necrosis factor alpha levels and improved survival. IL-10 could be potentially useful for the treatment of GBS sepsis.